# NHLBI CATALYZE COORDINATING CENTER SUPPORT SERVICES

> **NIH NIH N02** · RESEARCH TRIANGLE INSTITUTE · 2024 · $3,565,314

## Abstract

CatPC will support preclinical development activities from end-stage proof-of-concept, through preclinical development, and US regulatory approval filing. Technologies that are being repurposed should demonstrate access to existing regulatory data relevant to the new indication, and the intellectual property rights and/or partnerships to proceed with development for the new indication. Projects may enter via successful completion and approval for advancement of a technology from other Catalyze initiatives, or may apply directly to CatPC to support technology development activities that fall within the program scope. For successful applications, CatPC will fill the gap between end stage optimization conducted during the product definition stage, and regulatory approval filing in anticipation of initiation of clinical studies. Thus, CatPC will be a critical and required portion of the Catalyze Program to provide a continuous translational pipeline from discovery to first in human trials.

## Key facts

- **NIH application ID:** 11077738
- **Project number:** 92023A04092023F00001-P00001-0-1
- **Recipient organization:** RESEARCH TRIANGLE INSTITUTE
- **Principal Investigator:** DIANA SEVERYNSE-STEVENS
- **Activity code:** N02 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $3,565,314
- **Award type:** —
- **Project period:** 2023-09-25 → 2024-09-24

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11077738

## Citation

> US National Institutes of Health, RePORTER application 11077738, NHLBI CATALYZE COORDINATING CENTER SUPPORT SERVICES (92023A04092023F00001-P00001-0-1). Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/grant/nih/11077738. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*